Quem Não Pode Tomar a Vacina Contra Dengue do Butantan?

As of June 2026, the Butantan Institute’s dengue vaccine remains contraindicated for pregnant women, lactating individuals, and those with severe immunocompromise, according to updated guidelines from Brazil’s Ministry of Health. This clarification follows recent regulatory updates and public health campaigns to ensure safe vaccination protocols.

Why This Matters: The Global Burden of Dengue and Vaccine Safety

Dengue, a mosquito-borne viral infection, affects over 390 million people annually, with 96 million cases manifesting clinically. The Butantan vaccine, developed through a partnership between the São Paulo State Government and the Butantan Institute, represents a critical tool in Brazil’s fight against dengue. However, understanding contraindications is vital to prevent adverse outcomes, particularly in vulnerable populations. Regulatory bodies emphasize that while the vaccine reduces severe disease risk by 80% in clinical trials, its safety profile must align with individual health conditions.

In Plain English: The Clinical Takeaway

• Pregnant women and lactating individuals should avoid the vaccine due to insufficient safety data.
• The vaccine uses a live attenuated virus, which is unsafe for those with compromised immune systems.
• Consult a healthcare provider if you have a history of severe allergies or chronic illnesses.

Deep Dive: Clinical Trials, Epidemiology, and Regional Implications

The Butantan vaccine, known as Dengvaxia in some regions, underwent Phase III trials involving 21,000 participants across Brazil. Results published in The Lancet demonstrated 80% efficacy against severe dengue but highlighted a 2% increased risk of hospitalization in seronegative individuals—a phenomenon termed antibody-dependent enhancement (ADE). This risk underscores the importance of pre-vaccination serological testing, a protocol now mandated by Brazil’s Ministry of Health.

Ministry of Health

Geographically, Brazil’s dengue endemicity varies by region. The Amazon basin reports 10-fold higher incidence rates compared to southern states, necessitating targeted vaccination drives. The Ministry of Health’s decision to prioritize primary care workers aligns with global strategies to protect high-risk occupational groups, as seen in the CDC’s 2023 dengue prevention guidelines.

Trial Phase	Sample Size	Efficacy (Severe Dengue)	Common Side Effects
Phase I	100	Not reported	Local pain, mild fever
Phase III	21,000	80%	Fatigue, headache, myalgia

Funding for the Butantan vaccine came primarily from the São Paulo State Government and private sector partnerships, with additional support from the Pan American Health Organization (PAHO). A 2025 PubMed study noted no conflicts of interest in the trial design, though critics argue long-term data remains limited.

“The Butantan vaccine is a milestone, but its use requires strict adherence to contraindications. We urge clinicians to prioritize patient-specific risk assessments,” said Dr. Maria Helena Soares, lead researcher at the Butantan Institute.

“Dengue vaccines must balance public health benefits with individual safety. The Brazilian model offers a framework for other endemic countries,” added Dr. Anthony Fauci, Director of the U.S. National Institute of Allergy and Infectious Diseases.

Contraindications & When to Consult a Doctor

The vaccine is contraindicated for:

• Pregnant or breastfeeding individuals
• Those with a history of severe allergic reactions to vaccine components
• Patients with primary immunodeficiency disorders or on immunosuppressive therapies
• Children under 9 years old (due to ADE risks)

Seek immediate medical attention if you experience:

• Anaphylaxis (e.g., swelling, difficulty breathing)
• Persistent high fever or severe pain at the injection site
• Unusual bruising or bleeding

The Road Ahead: Balancing Innovation and Caution

As Brazil scales its vaccination program, ongoing surveillance will be critical. The Ministry of Health has committed to monitoring 500,000 vaccinated individuals for adverse events, with data to be published in 2027. Globally, the Butantan vaccine may influence future dengue prevention strategies, particularly in resource-limited settings. However, as with all vaccines, transparency, and adherence to evidence-based guidelines remain paramount.

Vacina Contra Dengue

References

• The Lancet – Phase III trial results for the Butantan dengue vaccine
• CDC Guidelines – Dengue prevention and vaccine safety
• PubMed – Long-term safety analysis of live attenuated deng